COVID Vaccine Injuries: How the Public Can Push for Reform
COVID-19 vaccines were administered on an unprecedented scale in the United States. Hundreds of millions of doses were distributed nationwide in a short period of time.
Yet individuals who allege injury from COVID-19 vaccines are not eligible to file claims in the Vaccine Injury Compensation Program (VICP).
Instead, COVID vaccine injury claims must be filed through a different federal system: the Countermeasures Injury Compensation Program (CICP).
Understanding the difference between the CICP and the VICP — and the realistic chances of compensation under each — is essential to understanding the current state of COVID vaccine injury compensation policy in 2026.
Why COVID-19 Vaccines Are Not Covered by the Vaccine Injury Compensation Program (VICP)
The Vaccine Injury Compensation Program (VICP) was created under the National Childhood Vaccine Injury Act of 1986. The VICP covers vaccines that:
Are recommended for routine administration to children or pregnant women; and
Are subject to a federal excise tax that funds the Vaccine Injury Compensation Trust Fund.
COVID-19 vaccines were authorized and deployed under emergency authority through the Public Readiness and Emergency Preparedness (PREP) Act. Because they were classified as emergency countermeasures rather than incorporated through the statutory Vaccine Act process, they were not automatically added to the Vaccine Injury Table.
As a result, COVID vaccine injury claims were routed to the Countermeasures Injury Compensation Program (CICP), not the VICP.
This was a policy decision — not a constitutional limitation.
The Secretary of Health and Human Services (HHS) has statutory authority to revise the Vaccine Injury Table “by regulation.” That authority could be used to add COVID-19 vaccines to the VICP framework through formal rulemaking.
What Are the Realistic Chances of Compensation Under the CICP?
The Countermeasures Injury Compensation Program (CICP) operates very differently from the Vaccine Injury Compensation Program (VICP).
Unlike the VICP, the CICP:
Does not compensate pain and suffering
Does not pay attorney fees or litigation costs
Does not provide hearings before independent Special Masters
Provides extremely limited appeal rights
Imposes strict filing deadlines
These structural differences matter.
According to publicly available HHS data, more than 14,000 COVID-19 countermeasure injury claims have been filed with the CICP since the start of the pandemic.
Of those claims:
Fewer than 100 have been deemed eligible for compensation.
Only approximately 40 to 50 claims have resulted in actual payment.
The overwhelming majority of COVID vaccine injury claims remain either pending or denied.
This means that well over 99% of filed COVID vaccine injury claims have not resulted in compensation under the CICP.
“Pending” does not mean likely to be compensated. It simply means the claim has not yet completed review.
These statistics do not suggest that every filed claim is valid. However, they demonstrate that the realistic probability of compensation under the CICP has been extremely low relative to the volume of claims submitted.
For individuals seeking compensation for COVID-19 vaccine injuries, the current CICP framework offers a limited and highly restrictive pathway.
Why Has HHS Not Added COVID-19 Vaccines to the VICP?
The Secretary of HHS has clear authority under the Vaccine Act to revise the Vaccine Injury Table through notice-and-comment rulemaking.
That authority could be used to move COVID-19 vaccines into the Vaccine Injury Compensation Program.
Why has that not happened?
Several plausible policy factors may explain the delay:
1. Emergency Framework Inertia
COVID-19 vaccines were deployed under the PREP Act emergency structure. Transitioning them into the VICP would require regulatory action and coordination with Congress to impose the required excise tax.
2. Political Sensitivity
COVID vaccine policy remains politically polarized. Some policymakers may fear that adding COVID vaccines to the VICP would be misinterpreted as an admission that the vaccines are broadly unsafe, even though the VICP routinely covers vaccines with strong safety records.
3. Administrative Capacity Concerns
Adding COVID vaccines to the VICP would likely increase filings significantly. Without increasing the number of Special Masters and court staff, case backlog could worsen. Some officials may hesitate to expand coverage without modernizing administrative capacity.
4. Optics vs. Structure
There may be concern about media interpretation. However, compensation systems exist precisely to address rare injuries without undermining vaccine policy or public health objectives.
None of these considerations eliminate the Secretary’s legal authority to act. They help explain why the issue remains unresolved.
What Would Change If COVID Vaccines Were Added to the VICP?
If COVID-19 vaccines were added to the Vaccine Injury Compensation Program:
Claims would be heard by independent Special Masters in the U.S. Court of Federal Claims.
Pain and suffering compensation would be available (subject to statutory caps).
Attorney fees would be paid by the program.
Decisions would be published and subject to structured appellate review.
Funding would come from the Vaccine Injury Compensation Trust Fund.
The VICP is a self-funded compensation system, financed through per-dose excise taxes paid by vaccine manufacturers. It does not rely on general taxpayer revenue.
Adding COVID vaccines to the VICP would require Congress to impose an excise tax on COVID vaccine doses — aligning manufacturer liability protections with structured compensation funding.
Why Adding COVID Vaccines Should Be Paired with HR 5142
If COVID vaccines are added to the VICP, case filings will increase.
HR 5142 — the Vaccine Injury Compensation Modernization Act — proposes:
Increasing the number of Special Masters
Raising and indexing compensation caps for pain and suffering
Expanding vaccine coverage
Modernizing the excise tax structure
Adding COVID vaccines to the VICP without expanding adjudicative capacity could increase delays.
Pairing coverage expansion with modernization reforms ensures that the Vaccine Injury Compensation Program remains fair, efficient, and capable of handling increased caseloads.
What the Public Can Do to Advocate for COVID Vaccine Compensation Reform
If you believe COVID-19 vaccine injuries should be eligible for compensation under the VICP, civic engagement matters.
You can contact your members of Congress:
Find your U.S. Representative:
https://www.house.gov/representatives/find-your-representative
Find your U.S. Senators:
https://www.senate.gov/senators/senators-contact.htm
When contacting them, focus on:
Structural fairness in COVID vaccine injury compensation
Aligning liability protections with meaningful compensation remedies
Supporting legislation such as HR 5142
Encouraging HHS to initiate rulemaking to add COVID vaccines to the Vaccine Injury Table
Communications should be respectful, fact-based, and policy-focused.
Final Perspective: The Future of COVID Vaccine Injury Compensation
COVID-19 vaccines were administered at historic scale.
If rare injuries occurred — and credible scientific evidence supports that some have — a structured, judicial compensation pathway should exist.
The current CICP system has compensated only a very small fraction of filed COVID vaccine injury claims.
The Vaccine Injury Compensation Program was built precisely to balance public health stability with fair compensation for rare vaccine injuries.
The authority to include COVID vaccines in the VICP exists.
The structural funding mechanism exists.
The question is whether policymakers will align compensation policy with the modern vaccine landscape.
Consistency strengthens trust.
Transparency strengthens confidence.
Fair compensation strengthens both.